Update in treatment options for psoriatic arthritis

References

• Zink A, Thiele K, Huscher D et al.; German Collaborative Arthritis Centres. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol.33(1), 86–90 (2006).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Farewell VT, Nadeau C.Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J. Rheumatol.22(4), 675–679 (1995).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J. Rheumatol.28(5), 1045–1048 (2001).
   PubMed Web of Science ®Google Scholar
• Khan M, Schentag C, Gladman DD.Clinical and radiological changes during psoriatic arthritis disease progression. J. Rheumatol.30(5), 1022–1026 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum.54(8), 2665–2673 (2006).
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Mejias E et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum.39(12), 2013–2020 (1996).
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Nash P, Gladman D et al.; Treatment of Psoriatic Arthritis study group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum.50(6), 1939–1950 (2004).
   PubMed Web of Science ®Google Scholar
• Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J. Cutan. Med. Surg.11(2), 57–66 (2007).
   PubMed Web of Science ®Google Scholar
• Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am. J. Ophthalmol.139(1), 106–111 (2005).
   PubMed Web of Science ®Google Scholar
• Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr. Rheumatol. Rep.8(5), 355–363 (2006).
   PubMedGoogle Scholar
• Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J. Rheumatol.33(2), 210–212 (2006).
   PubMed Web of Science ®Google Scholar
• Zenz R, Eferl R, Kenner L et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature15, 437(7057), 369–375 (2005).
   Google Scholar
• de Vlam K, Lories RJ. Remission in psoriatic arthritis. Curr. Rheumatol. Rep.10(4), 297–302 (2008).
   PubMedGoogle Scholar
• Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann. Rheum. Dis. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin. Exp. Rheumatol.24(6 Suppl. 43), S83–S87 (2006).
   Google Scholar
• Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin. Arthritis Rheum.37(3), 164–173 (2007).
   PubMed Web of Science ®Google Scholar
• Scarpa R, Peluso R, Atteno M et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin. Rheumatol.27(7), 823–826 (2008).
   PubMed Web of Science ®Google Scholar
• Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J. Rheumatol.35(3), 469–471 (2008).
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP. Leflunomide in psoriatic arthritis. Autoimmun. Rev.6(8), 511–514 (2007).
   PubMed Web of Science ®Google Scholar
• Malesci D, Tirri R, Buono R, LaMontagna G. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin. Exp. Rheumatol.25(6), 881–884 (2007).
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AW, Westhovens R et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann. Rheum. Dis.64(6), 859–864 (2005).
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology47(6), 872–876 (2008).
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet357(9271), 1842–1847 (2001).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet356(9227), 385–390 (2000).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol.55(4), 598–606 (2006).
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K et al.; IMPACT 2 trial investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum Dis.64(8), 1150–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum.56(2), 476–488 (2007).
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum.52(4), 1227–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann. Rheum. Dis.65(8), 1038–1043 (2006).
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, van der Heijde D et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J. Rheumatol.35(5), 869–876 (2008).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Krueger GG, Beutler A et al.; IMPACT 2 study group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann. Rheum. Dis.66(4), 498–505 (2007).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum.50(7), 2264–2272 (2004).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mease PJ, Thomson GT; M02–570 study group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J. Rheumatol.34(5), 1040–1050 (2007).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum.60(4), 976–986 (2009).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann. Rheum. Dis.66(2), 163–168 (2007).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis.68(5), 702–709 (2009).
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Gülfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the south Swedish Arthritis Treatment Group register. Ann. Rheum. Dis.67(3), 364–369 (2008).
   PubMed Web of Science ®Google Scholar
• Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann. Rheum. Dis.67(11), 1650–1651 (2008).
   PubMed Web of Science ®Google Scholar
• de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford)45(3), 321–324 (2006).
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F, Marocchi E et al. Switching tumour necrosis factor a antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann. Rheum Dis.66(10), 1393–1397 (2007).
   PubMed Web of Science ®Google Scholar
• Coates LC, Cawkwell LS, Ng NW et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann. Rheum. Dis.67(5), 717–719 (2008).
   PubMed Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med.198(12), 1951–1957 (2003).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C et al.; CNTO (1275) Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med.356(6), 580–592 (2007).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet371(9625), 1665–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet371(9625), 1675–1684 (2008).
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet373(9664), 633–640 (2009).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Inman RD, Cook RJ et al. International spondyloarthritis interobserver reliability exercise – the INSPIRE study: I. Assessment of spinal measures. J. Rheumatol.34(8), 1733–1739 (2007).
   PubMed Web of Science ®Google Scholar
• Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J. Rheumatology32(9), 1745–1750 (2005).
   PubMed Web of Science ®Google Scholar
• D’Agostino MA, Breban M, Said-Nahal R, Dougados M. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum.46(3), 840–841 (2002).
   PubMed Web of Science ®Google Scholar
• D’Agostino MA, Said-Nahal R, Hacquard-Bouder C, Brasseur JL, Dougados M, Breban M. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum.48(2), 523–533 (2003).
   PubMed Web of Science ®Google Scholar
• Marzo-Ortega H, McGonagle D, Rhodes LA et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann. Rheum. Dis.66(6), 778–781 (2007).
   PubMed Web of Science ®Google Scholar
• Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst. Rev.2, CD004524 (2004).
   Google Scholar
• Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J. Rheumatol.27(3), 714–718 (2000).
   PubMed Web of Science ®Google Scholar
• Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin. Exp. Rheumatol.13(5), 589–593 (1995).
   PubMed Web of Science ®Google Scholar
• Wollina U, Ständer K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis – short- and long-term toxicity in 104 patients. Clin. Rheumatol.20(6), 406–410 (2001).
   PubMed Web of Science ®Google Scholar
• Whiting-O’Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am. J. Med.90(6), 711–716 (1991).
   PubMed Web of Science ®Google Scholar
• Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br. J. Dermatol.144(1), 100–103 (2001).
   PubMed Web of Science ®Google Scholar
• Sund S, Førre O, Berg KJ, Kvien TK, Hovig T. Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin. Nephrol.41(1), 33–40 (1994).
   PubMed Web of Science ®Google Scholar
• Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann. Rheum Dis.67(6), 855–859 (2008).
   PubMed Web of Science ®Google Scholar
• Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J. Rheumatol.35(5), 883–890 (2008).
   PubMed Web of Science ®Google Scholar
• Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J. Rheumatol.25(10), 1957–1961 (1998).
   PubMed Web of Science ®Google Scholar
• Macchioni P, Boiardi L, Cremonesi T et al. The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol. Int.18(1), 27–33 (1998).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J. Rheumatol.33(4), 712–721 (2006).
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis.68(9), 1387–1394 (2008).
   PubMed Web of Science ®Google Scholar
• de Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J. Rheumatol.35(7), 1443–1448 (2008).
   PubMed Web of Science ®Google Scholar
• Lories RJ, Derese I, Luyten FP, de Vlam K. Activation of nuclear factor κ B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin. Exp. Rheumatol.26(1), 96–102 (2008).
   PubMed Web of Science ®Google Scholar
• Wassenberg S, Fischer-Kahle V, Herborn G, Rau R. A method to score radiographic change in psoriatic arthritis. Z. Rheumatol.60(3), 156–166 (2001).
   PubMed Web of Science ®Google Scholar